Semaglutide provides benefits for men and women with obesity-related heart failure, potentially with weight-loss independent effects on the cardiovascular system.
Sex differences in obesity-related HFpEF are crucial, with women facing amplified symptoms and limitations, highlighting the importance of understanding and addressing these disparities.
Collection
[
|
...
]